.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,507,397

« Back to Dashboard

Details for Patent: 7,507,397

Title:Delivery of muscle relaxants through an inhalation route
Abstract: The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing muscle relaxants that are used in inhalation therapy. In a method aspect of the present invention, a muscle relaxant is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of a muscle relaxant, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% muscle relaxant degradation products. In a kit aspect of the present invention, a kit for delivering a muscle relaxant through an inhalation route is provided which comprises: a) a coating of a muscle relaxant and b) a device for dispensing said coating a muscle relaxant as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D. (Princeton, NJ), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Filing Date:Sep 19, 2006
Application Number:11/523,685
Claims:1. A condensation aerosol for delivery of quinine formed by heating a composition containing quinine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of quinine and less than 5 percent by weight of quinine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

3. The condensation aerosol according to claim 1, or claim 2, wherein the geometric standard deviation around the MMAD is less than 3.0.

4. A condensation aerosol for delivery of chlorzoxazone formed by heating a composition containing chlorzoxazone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of chlorzoxazone and less than 5 percent by weight of chlorzoxazone degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

5. The condensation aerosol according to claim 4, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

6. The condensation aerosol according to claim 4 or claim 5, wherein the geometric standard deviation around the MMAD is less than 3.0.

7. A condensation aerosol for delivery of carisoprodol formed by heating a composition containing carisoprodol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of carisoprodol and less than 5 percent by weight of carisoprodol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

8. The condensation aerosol according to claim 7, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

9. The condensation aerosol according to claim 7 or claim 8, wherein the geometric standard deviation around the MMAD is less than 3.0.

10. A condensation aerosol for delivery of cyclobenzaprine formed by heating a composition containing cyclobenzaprine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of cyclobenzaprine and less than 5 percent by weight of cyclobenzaprine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

11. The condensation aerosol according to claim 10, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

12. The condensation aerosol according to claim 10 or claim 11, wherein the geometric standard deviation around the MMAD is less than 3.0.

13. A method of forming a quinine containing aerosol comprising: (a) heating a composition containing quinine coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of quinine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

14. The method according to claim 13, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

15. The method according to claim 14, wherein the coated composition comprises at least 10 percent by weight of quinine.

16. A method of forming a chlorzoxazone containing aerosol comprising: (a) heating a composition containing chlorzoxazone coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of chlorzoxazone degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

17. The method according to claim 16, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

18. The method according to claim 17, wherein the coated composition comprises at least 10 percent by weight of chlorzoxazone.

19. A method of forming a carisoprodol containing aerosol comprising: (a) heating a composition containing carisoprodol coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of carisoprodol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

20. The method according to claim 19, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

21. The method according to claim 20, wherein the coated composition comprises at least 10 percent by weight of carisoprodol.

22. A method of forming a cyclobenzaprine containing aerosol comprising: (a) heating a composition containing cyclobenzaprine coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of cyclobenzaprine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

23. The method according to 22, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

24. The method according to claim 23 wherein the coated composition comprises at least 10 percent by weight of cyclobenzaprine.

25. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisoprodol and cyclobenzaprine, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug quinine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

26. A method of forming a drug containing aerosol comprising: (a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisoprodol, and cyclobenzaprine, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

27. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool.

28. The condensation aerosol according to claim 5, wherein the condensing comprises allowing the vapor to cool.

29. The condensation aerosol according to claim 8, wherein the condensing comprises allowing the vapor to cool.

30. The condensation aerosol according to claim 11, wherein the condensing comprises allowing the vapor to cool.

31. The method according to claim 14, wherein the condensing comprises allowing the vapor to cool.

32. The method according to claim 17, wherein the condensing comprises allowing the vapor to cool.

33. The method according to claim 20, wherein the condensing comprises allowing the vapor to cool.

34. The method according to claim 23, wherein the condensing comprises allowing the vapor to cool.

35. The method according to claim 25, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

36. The method according to claim 35, wherein the coated composition comprises at least 10 percent by weight of the drug.

37. The method according to claim 35, wherein the condensing comprises allowing the vapor to cool.

38. The method according to claim 26, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

39. The method according to claim 38, wherein the coated composition comprises at least 10 percent by weight of the salt form of the drug.

40. The method according to claim 38, wherein the condensing comprises allowing the vapor to cool.

41. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisoprodol, and cyclobenzaprine, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

42. The method according to claim 41, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

43. The method according to claim 42, wherein the condensation aerosol is formed at a rate greater than 0.75 mg/second.

44. The method according to claim 43, wherein the condensation aerosol is formed at a rate greater than 1 mg/second.

45. The method according to claim 44, wherein the condensation aerosol is formed at a rate greater than 2 mg/second.

46. The method according to claim 42, wherein the condensing comprises allowing the vapor to cool.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc